Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center.
作者信息
Le Thomas K, Newland Elizabeth Schoenberg, Brown Isabelle, Goldberg Rebecca, Semenov Yevgeniy R, Kwatra Shawn G
机构信息
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
J Am Acad Dermatol. 2024 Mar;90(3):648-650. doi: 10.1016/j.jaad.2023.10.065. Epub 2023 Nov 17.
Abstract
摘要
相似文献
1
Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center.皮肤免疫相关不良事件负担及其对免疫治疗的影响：对一家三级医疗免疫治疗中心经验的回顾性分析
J Am Acad Dermatol. 2024 Mar;90(3):648-650. doi: 10.1016/j.jaad.2023.10.065. Epub 2023 Nov 17.
2
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.接受替莫唑胺和免疫检查点抑制剂治疗的患者皮肤免疫相关不良事件风险增加：一项多医院队列研究。
J Am Acad Dermatol. 2023 Jun;88(6):1265-1270. doi: 10.1016/j.jaad.2023.02.017. Epub 2023 Mar 21.
3
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.抗 PD-1 癌症免疫治疗相关的预先存在的自身免疫性疾病和免疫相关不良事件：来自加拿大免疫肿瘤学风湿病学研究小组的全国病例系列。
Cancer Immunol Immunother. 2021 Aug;70(8):2197-2207. doi: 10.1007/s00262-021-02851-5. Epub 2021 Jan 20.
4
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.癌症类型和组织学影响皮肤免疫治疗的毒性：一项多机构队列研究。
Br J Dermatol. 2024 Jun 20;191(1):117-124. doi: 10.1093/bjd/ljae053.
5
Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.皮肤科咨询对接受检查点抑制剂相关皮肤毒性治疗患者生存的影响。
Br J Dermatol. 2021 Sep;185(3):627-635. doi: 10.1111/bjd.20074. Epub 2021 May 17.
6
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.接受度普利尤单抗治疗皮肤免疫相关不良事件的免疫治疗患者的长期死亡率结局。
medRxiv. 2025 Jan 8:2025.01.07.25320156. doi: 10.1101/2025.01.07.25320156.
7
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.皮肤免疫相关不良反应与接受免疫检查点抑制剂治疗的晚期癌症患者的总生存期延长相关：一项多机构队列研究。
J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048. Epub 2023 Feb 2.
8
Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.羟氯喹是一种安全有效的免疫检查点抑制剂诱导性炎症性关节炎的类固醇节约剂。
Clin Rheumatol. 2019 May;38(5):1513-1519. doi: 10.1007/s10067-019-04451-2. Epub 2019 Jan 30.
9
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.黑色素瘤类型对免疫检查点抑制剂治疗中皮肤免疫相关不良事件的发生率和下游影响的影响。
J Am Acad Dermatol. 2023 Jun;88(6):1308-1316. doi: 10.1016/j.jaad.2023.02.014. Epub 2023 Feb 22.
10
Multiple sclerosis outcomes after cancer immunotherapy.癌症免疫疗法治疗多发性硬化症的结果。
Clin Transl Oncol. 2019 Oct;21(10):1336-1342. doi: 10.1007/s12094-019-02060-8. Epub 2019 Feb 20.
引用本文的文献
1
Dermatologic toxicities related to cancer immunotherapy.与癌症免疫治疗相关的皮肤毒性
Toxicol Rep. 2025 Apr 5;14:102021. doi: 10.1016/j.toxrep.2025.102021. eCollection 2025 Jun.
本文引用的文献
1
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.免疫检查点抑制剂相关皮肤毒性：一项观察性、药物警戒研究。
J Invest Dermatol. 2022 Nov;142(11):2896-2908.e4. doi: 10.1016/j.jid.2022.04.020. Epub 2022 May 20.
2
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.免疫检查点抑制剂治疗的皮肤不良反应：反应性皮肤病的发生率和类型。
J Dermatolog Treat. 2022 May;33(3):1691-1695. doi: 10.1080/09546634.2021.1898529. Epub 2021 Mar 23.
3
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
4
Cutaneous Adverse Reactions of Anticancer Agents.抗肿瘤药物的皮肤不良反应。
Dermatol Clin. 2019 Oct;37(4):555-568. doi: 10.1016/j.det.2019.05.013. Epub 2019 Jul 27.
5
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.管理免疫检查点抑制剂相关毒性：癌症免疫治疗学会（SITC）毒性管理工作组的共识建议。
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
Zotero 插件